Arix Bioscience, a healthcare and life science company, today announces planned changes to its executive team to prepare for its next phase of growth and development. Dr Joe Anderson, who has served as Chief Executive Officer of Arix since its inception in 2016, will transition to Chief Investment Officer. He will continue to Chair the Investment Committee and as of today, September 4 2018, will step down from the Board of Arix. Executive Chairman of Arix, Jonathan Peacock, will assume corporate and operating responsibilities and, working closely with the Board of Arix, will lead the process of recruiting a Chief Executive Officer.
EIB incentivises bioeconomy investments
Latest NewsThe European Investment Bank (EIB) has issued its first Sustainability Awareness Bond worth €500m to support investments into water projects – health and nutrition to follow.
The future of agrochemistry
BackgroundOne of the world’s largest and most controversial mergers in the past few years was sealed in early June. German pharma and chemistry company Bayer has taken over US competitor Monsanto, forming the largest integrated provider of seeds, agrochemicals and digital farming solutions on the planet. The acquisition is part of a recent US$170bn deal binge that is already having a profound impact on the future of global agriculture.
The new Flexcell® FX-6000 Tension System and other cell culture products to be shown at the DGZ conference in Leipzig
ProductsDunn Labortechnik will present a variety of cell culture products and the new Flexcell® FX-6000 Tension System from the American company Flexcell International at the International Meeting of the German Society for Cell Biology (DGZ) from 17th to 19th September, on booth no. 5 in the auditorium building of the University of Leipzig.
New antibiotics on the block
Latest NewsAround 300 international AMR experts met at ESCMID-ASM drug development conference in Lisbon to discuss the latest progress in the field.
Adaptimmune raises US$100m
Latest NewsOxford-based Adaptimmune Therapeutics plc has raised US$100m in a registered direct offering of American Depositary Shares (ADS).
CAR-Ts: Novartis wins UK
Latest NewsThe NHS England announces it will reimburse Novartis’ CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse.
Changes at Arix Bioscience
AppointmentsArix Bioscience, a healthcare and life science company, today announces planned changes to its executive team to prepare for its next phase of growth and development. Dr Joe Anderson, who has served as Chief Executive Officer of Arix since its inception in 2016, will transition to Chief Investment Officer. He will continue to Chair the Investment Committee and as of today, September 4 2018, will step down from the Board of Arix. Executive Chairman of Arix, Jonathan Peacock, will assume corporate and operating responsibilities and, working closely with the Board of Arix, will lead the process of recruiting a Chief Executive Officer.
Evox raises €37m in Series B round
Latest NewsExosome drug delivery specialist Evox Therapeutics Ltd has closed a €37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.
New Secretary General & Directors at EuropaBio
AppointmentsEuropaBio today confirmed the appointment of Joanna Dupont-Inglis as its new Secretary General.
Commenting on this promotion, EuropaBio chair, Tjerk de Ruiter, said Joanna has an excellent track record of leadership and engagement in this sector. Her experience will be valuable in working together with an increasingly broad community of stakeholders to ensure that the benefits of biotech can be accessed in Europe”.
Sanofi gets the EU’s ok for caplacizumab
Latest NewsThe EU approved Sanofi’s Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday.